… jump in standalone net profit for the first quarter of FY26. The company … and better operating efficiency. Revenue from operations stood at Rs … market conditions. After its Q1 results, here’s what … deploy today? Put it in pharma funds, says Sandeep Tandon ( …

… financial results for the first quarter of Fiscal year 2026. … and CDMO businesses. Total revenue for the quarter stood … that partners with innovator pharmaceutical and biotech companies to … regulations that apply to pharmaceuticals, increasing competition in …

… 1.23%), a pharmaceutical company focused on therapies … revenue. This period marked a return to profitability … as provided in Q1 2025 earnings report. Puma Biotechnology… could cause revenue variability quarter to quarter. Royalty revenue, reflecting sub …

… Pharmaceuticals  Emcure Pharmaceuticals Ltd reported a strong performance for the first quarter ended … year (YoY) increase in revenue from operations at ₹2,101 … 8 per cent rise in profit after tax (PAT) at … across all businesses in Q1. We continue to augment …

… YoY) surge in consolidated net profit for the June quarter. The … in Q1FY25. After the Q1 results, here is what … It also highlighted strong transaction revenue growth, especially from the Sensex … deploy today? Put it in pharma funds, says Sandeep Tandon ( …

… products and services for pharmaceutical, biotechnology and academic … While overall spending on pharmaceutical research remained restrained, the … 2.5% in the first quarter of 2025. Challenging … saw the highest quarterly revenue for Semiconductor Materials …

has reported Consolidated financial results for the period ended June 30, 2025. Financial Results (Q1 FY2026) - QoQ Comparison The company has reported total income of Rs. 559.06 crores during the period ended June 30, 2025 as compared to Rs. 532.31 crores …

… results for the fiscal first quarter ended June 30, … period. The Fiscal First Quarter 2026 conference call information … the accelerated timeline to revenues for veterinary medical devices … than more stringently regulated pharmaceuticals and biologics. PetVivo …

WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal first quarter …

… of $0.95 in Q1, up approximately 6% versus … International OTC Healthcare: Fiscal first quarter 2026 revenues of $37.0 million … definitive agreement to acquire Pillar5 Pharma Inc. (“Pillar5”), a … long-term capacity. For profitability, we now anticipate EPS …